ACLY and metabolic dysfunction-associated steatotic liver disease: By reducing the expression of Acc, Me1, Fasn, Acly, this leads to an inhibition of the synthesis of cholesterol and fatty acids, reducing body fat accumulation, and reduce body weight of T2DM with NAFLD mice, while inhibiting the expression of Aox1 and Acot2, promotes fatty acid β-oxidation.